Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07517068 · ClinicalTrials.gov registry record · Early Phase 1
The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
A Early Phase 1 study, sponsored by University of California, Riverside.
- Active
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT07517068 is a Early Phase 1 study that is active but no longer recruiting, run by University of California, Riverside. The registered enrollment target is 19 participants.
The verdict
NCT07517068, a Early Phase 1 study, is active but no longer recruiting, sponsored by University of California, Riverside.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.
Interventions
- DEVICE Placebo Arm
- DRUG ACETAZOLAMIDE oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-12-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07517068
The ClinicalTrials.gov registry entry for NCT07517068 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Riverside, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Arm is the first listed.
NCT07517068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07517068 about?
NCT07517068 is a clinical study titled "The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude". High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated...
What is the current status of trial NCT07517068?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2025-09-17. Estimated completion is 2026-12-15.
What interventions are being tested in trial NCT07517068?
The interventions under investigation include: Placebo Arm (DEVICE), ACETAZOLAMIDE oral capsule (DRUG).
Who is sponsoring clinical trial NCT07517068?
This trial is sponsored by University of California, Riverside, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.